DE60323749D1 - Substituierte pyrroline als kinase inhibitoren - Google Patents

Substituierte pyrroline als kinase inhibitoren

Info

Publication number
DE60323749D1
DE60323749D1 DE60323749T DE60323749T DE60323749D1 DE 60323749 D1 DE60323749 D1 DE 60323749D1 DE 60323749 T DE60323749 T DE 60323749T DE 60323749 T DE60323749 T DE 60323749T DE 60323749 D1 DE60323749 D1 DE 60323749D1
Authority
DE
Germany
Prior art keywords
kinase inhibitors
pyrrolins
substituted
kinase
dual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60323749T
Other languages
English (en)
Inventor
Han-Cheng Zhang
Bruce E Maryanoff
David F Mccomsey
Kimberly White
Hong Ye
Leonard Hecker
Bruce R Conway
Keith Demarest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60323749D1 publication Critical patent/DE60323749D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60323749T 2002-06-05 2003-06-04 Substituierte pyrroline als kinase inhibitoren Expired - Fee Related DE60323749D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38600202P 2002-06-05 2002-06-05
PCT/US2003/017518 WO2003103663A2 (en) 2002-06-05 2003-06-04 Substituted pyrrolines as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60323749D1 true DE60323749D1 (de) 2008-11-06

Family

ID=29736129

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323749T Expired - Fee Related DE60323749D1 (de) 2002-06-05 2003-06-04 Substituierte pyrroline als kinase inhibitoren

Country Status (9)

Country Link
US (4) US7232906B2 (de)
EP (1) EP1513520B1 (de)
JP (1) JP2005531607A (de)
AT (1) ATE409035T1 (de)
AU (1) AU2003240517A1 (de)
CA (1) CA2488798A1 (de)
DE (1) DE60323749D1 (de)
ES (1) ES2312785T3 (de)
WO (1) WO2003103663A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431166A1 (en) * 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
WO2003095452A1 (en) * 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ES2312785T3 (es) * 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
WO2004094422A1 (en) * 2003-03-27 2004-11-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ATE406365T1 (de) * 2003-06-13 2008-09-15 Janssen Pharmaceutica Nv Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren
AU2005205182B2 (en) * 2004-01-19 2009-07-16 Novartis Ag Indolylmaleimide derivatives
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US8771754B2 (en) * 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
JP5289769B2 (ja) * 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
EP1885454A2 (de) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten
KR20080023732A (ko) * 2005-07-11 2008-03-14 노파르티스 아게 인돌릴말레이미드 유도체
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1940411A4 (de) * 2005-09-29 2008-10-29 Janssen Pharmaceutica Nv Makroheterozyklische verbindungen als kinase-hemmer
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
RU2009110257A (ru) * 2006-08-23 2010-09-27 Новартис АГ (CH) Применение ингибиторов ркс, прежде всего производных индолилмалеимида для лечения глазных заболеваний
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074752A2 (en) * 2006-12-19 2008-06-26 Novartis Ag Indolylmaleimide derivatives as kinase inhibitors
ATE535241T1 (de) * 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2338486A1 (de) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Derivaten zurVerwendung in der Behandlung von Colon und Magen Adenocarzinoma
EP2343291A1 (de) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
EP2474541A1 (de) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren
JP2016508962A (ja) * 2012-12-10 2016-03-24 セントジーン アーゲー ガンを予防および治療するためのマレイミド誘導体の使用
CA2892927A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
EP3187495A1 (de) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
BR9710648A (pt) 1996-03-20 1999-08-17 Lilly Co Eli S¡ntese de indolilmaleimidas
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO1999042100A1 (fr) 1998-02-23 1999-08-26 Sagami Chemical Research Center Inhibiteurs de la mort cellulaire
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
KR100748386B1 (ko) * 2000-11-07 2007-08-10 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
CA2431166A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
WO2003095452A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
MXPA04012188A (es) 2002-06-05 2005-07-25 Johnson & Johnson Derivados de bisindolil-maleimida como inhibidores de cinasa.
ES2312785T3 (es) * 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
WO2004094422A1 (en) 2003-03-27 2004-11-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ATE406365T1 (de) 2003-06-13 2008-09-15 Janssen Pharmaceutica Nv Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren

Also Published As

Publication number Publication date
US20070213386A1 (en) 2007-09-13
WO2003103663A2 (en) 2003-12-18
US20100240650A1 (en) 2010-09-23
US20070213387A1 (en) 2007-09-13
JP2005531607A (ja) 2005-10-20
ATE409035T1 (de) 2008-10-15
WO2003103663A3 (en) 2004-07-08
US7608634B2 (en) 2009-10-27
US20040054180A1 (en) 2004-03-18
EP1513520A2 (de) 2005-03-16
EP1513520B1 (de) 2008-09-24
US7232906B2 (en) 2007-06-19
ES2312785T3 (es) 2009-03-01
US7759380B2 (en) 2010-07-20
AU2003240517A1 (en) 2003-12-22
CA2488798A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE326464T1 (de) Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren
ATE301661T1 (de) Makroheterocyclische verbindungen als kinase inhibitoren
NL301145I2 (nl) Tirbanibulin
ATE380175T1 (de) Pyrrolidine als dipeptidyl peptidase inhibitoren
ATE370943T1 (de) Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
DE60222667D1 (de) Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
SE0203713D0 (sv) Novel compounds
RS51445B (en) PYROLIDINDION SUBSTITUTED BY PIPERIDINE-PTHALAZONE AS PDE4 INHIBITORS
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
BRPI0409580A (pt) compostos de quinazolina
DE60329326D1 (de) Tace inhibitoren
CY1107287T1 (el) Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
EA200600945A1 (ru) Производные морфолина в качестве ингибиторов повторного захвата норадреналина
WO2007041195A3 (en) Macroheterocylic compounds as kinase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee